Please use this identifier to cite or link to this item: https://doi.org/10.1080/14760584.2023.2191716
DC FieldValue
dc.titleEffectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews
dc.contributor.authorTan, TT
dc.contributor.authorNg, HJ
dc.contributor.authorYoung, B
dc.contributor.authorKhan, BA
dc.contributor.authorShetty, V
dc.contributor.authorAzmi, N
dc.contributor.authorClissold, S
dc.date.accessioned2023-06-08T05:44:02Z
dc.date.available2023-06-08T05:44:02Z
dc.date.issued2023-01-01
dc.identifier.citationTan, TT, Ng, HJ, Young, B, Khan, BA, Shetty, V, Azmi, N, Clissold, S (2023-01-01). Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. Expert Review of Vaccines 22 (1) : 341-365. ScholarBank@NUS Repository. https://doi.org/10.1080/14760584.2023.2191716
dc.identifier.issn1476-0584
dc.identifier.issn1744-8395
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/241721
dc.description.abstractIntroduction: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including administration of booster doses, continues to be the most effective method for controlling COVID-19-related complications including progression to severe illness and death. However, there is mounting evidence that more needs to be done to protect individuals with compromised immune function. Areas covered: Here, we review the effectiveness of COVID-19 vaccination in immunocompromised patients, including those with primary immunodeficiencies, HIV, cancer (including hematological malignancies), solid organ transplant recipients, and chronic kidney disease, as reported in systematic reviews/meta-analyses published over a 12-month period in PubMed. Given the varied responses to vaccination in patients with compromised immune function, a major goal of this analysis was to try to identify specific risk-factors related to vaccine failure. Expert opinion: COVID-19 remains a global problem, with new variants of concern emerging at regular intervals. There is an ongoing need for optimal vaccine strategies to combat the pandemic. In addition, alternative treatment approaches are needed for immunocompromised patients who may not mount an adequate immune response to current COVID-19 vaccines. Identification of high-risk patients and the introduction of newer antiviral approaches such as monoclonal antibodies will offer physicians therapeutic options for such vulnerable individuals.
dc.publisherInforma UK Limited
dc.sourceElements
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectSARS-CoV-2
dc.subjectimmunocompromised patients
dc.subjectmonoclonal antibodies
dc.subjectHumans
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectSystematic Reviews as Topic
dc.subjectImmunocompromised Host
dc.subjectVaccination
dc.typeReview
dc.date.updated2023-06-07T16:29:19Z
dc.contributor.departmentMEDICINE
dc.description.doi10.1080/14760584.2023.2191716
dc.description.sourcetitleExpert Review of Vaccines
dc.description.volume22
dc.description.issue1
dc.description.page341-365
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Effectiveness of vaccination against SARS CoV 2 and the need for alternative preventative approaches in immunocompromised individuals a narrative.pdfPublished version1.08 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.